Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACE 2016

Next Previous
Drug Profile

ACE 2016

Alternative Names: ACE-2016

Latest Information Update: 27 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acepodia
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 27 Sep 2025 ACE 2016 is still in phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/unresectable) in USA (Parenteral) (NCT06415487)
  • 22 Aug 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/unresectable) in the US (Parenteral) (NCT06415487)
  • 04 Feb 2024 Acepodia plans a phase I trial for Solid tumours (Late stage disease, Metastatic disease) in USA (parenteral) in second half of 2024 (NCT06415487)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top